Jacobs Levy Equity Management Inc. Buys 390,301 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Jacobs Levy Equity Management Inc. grew its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 306.2% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 517,770 shares of the biopharmaceutical company’s stock after buying an additional 390,301 shares during the period. Jacobs Levy Equity Management Inc.’s holdings in Gilead Sciences were worth $37,927,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently bought and sold shares of GILD. Blue Trust Inc. increased its position in Gilead Sciences by 33.9% in the fourth quarter. Blue Trust Inc. now owns 3,700 shares of the biopharmaceutical company’s stock worth $276,000 after purchasing an additional 937 shares during the last quarter. Global Retirement Partners LLC increased its position in Gilead Sciences by 41.9% in the fourth quarter. Global Retirement Partners LLC now owns 6,744 shares of the biopharmaceutical company’s stock worth $580,000 after purchasing an additional 1,991 shares during the last quarter. Pinnacle Associates Ltd. increased its position in Gilead Sciences by 1.8% in the fourth quarter. Pinnacle Associates Ltd. now owns 59,814 shares of the biopharmaceutical company’s stock worth $4,846,000 after purchasing an additional 1,033 shares during the last quarter. Columbus Macro LLC bought a new stake in Gilead Sciences in the fourth quarter worth $1,363,000. Finally, Mirador Capital Partners LP increased its position in Gilead Sciences by 7.2% in the fourth quarter. Mirador Capital Partners LP now owns 11,144 shares of the biopharmaceutical company’s stock worth $903,000 after purchasing an additional 744 shares during the last quarter. Institutional investors own 83.67% of the company’s stock.

Analyst Ratings Changes

Several research analysts have commented on GILD shares. TD Cowen dropped their price objective on shares of Gilead Sciences from $90.00 to $85.00 and set a “buy” rating for the company in a research note on Friday, April 26th. Needham & Company LLC reaffirmed a “hold” rating on shares of Gilead Sciences in a research note on Friday, April 26th. Robert W. Baird reaffirmed a “neutral” rating and set a $80.00 price objective on shares of Gilead Sciences in a research note on Thursday, June 20th. Oppenheimer reaffirmed an “outperform” rating and set a $105.00 price objective on shares of Gilead Sciences in a research note on Friday, April 19th. Finally, StockNews.com raised shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating in a research note on Saturday, April 27th. Twelve analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and an average price target of $81.81.

Gilead Sciences Stock Up 0.4 %

Shares of GILD stock traded up $0.32 on Tuesday, hitting $78.05. The stock had a trading volume of 6,116,551 shares, compared to its average volume of 7,436,799. The company has a quick ratio of 0.94, a current ratio of 1.08 and a debt-to-equity ratio of 1.31. The business has a 50 day moving average price of $67.99 and a 200 day moving average price of $70.93. The company has a market cap of $97.24 billion, a PE ratio of 215.92, a P/E/G ratio of 3.28 and a beta of 0.18. Gilead Sciences, Inc. has a one year low of $62.07 and a one year high of $87.86.

Insider Activity at Gilead Sciences

In related news, insider Merdad Parsey sold 2,000 shares of Gilead Sciences stock in a transaction dated Monday, July 1st. The stock was sold at an average price of $68.63, for a total value of $137,260.00. Following the completion of the sale, the insider now directly owns 96,380 shares in the company, valued at $6,614,559.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.16% of the stock is currently owned by corporate insiders.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.